Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.
Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.
Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.
Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.
Quest Diagnostics (NYSE: DGX) reported strong Q1 2025 financial results with revenues of $2.65 billion, up 12.1% from 2024. The company achieved reported diluted EPS of $1.94 (up 12.8%) and adjusted diluted EPS of $2.21 (up 8.3%).
Key performance metrics include:
- Diagnostic Information Services revenues increased 12.7% to $2.59 billion
- Operating income rose 15.4% to $346 million
- Net income grew 13.2% to $220 million
- Cash from operations doubled to $314 million
Quest reaffirmed its full-year 2025 guidance with:
- Expected revenues between $10.70-10.85 billion
- Projected revenue growth of 8.4-9.9%
- Updated reported diluted EPS guidance of $8.62-8.87
- Maintained adjusted diluted EPS guidance of $9.55-9.80
Quest Diagnostics (NYSE: DGX) has launched AD-Detect™, a new laboratory blood test designed to confirm amyloid brain pathology in Alzheimer's disease patients with mild cognitive impairment or dementia. The test combines blood levels of amyloid beta 42/40 and p-tau217 to produce the AD-Detect Likelihood Score™.
Research presented at the 2025 AAN Annual Meeting demonstrated the test's 91% sensitivity and specificity, with positive and negative predictive values of 89% in mild cognitive impairment populations. The test showed strong performance in real-world specimens, categorizing 42% as high likelihood, 51% as low likelihood, and 7% as indeterminate for PET positivity.
The test is now available nationwide (except New York) through Quest's network of approximately 8,000 patient access points. This blood-based test offers a more affordable and less invasive alternative to traditional amyloid PET imaging and cerebral spinal fluid testing.
Quest Diagnostics (NYSE: DGX) has launched a new FDA-cleared HPV self-collection solution for cervical cancer screening. The service allows patients to collect their own specimens in healthcare settings and will be available at Quest's 2,000 patient service centers starting next month.
The solution utilizes Roche's FDA-cleared HPV self-collection technology, approved for use with their cobas® HPV test in May 2024. This initiative follows Quest's successful launch of self-collection services for STIs in October 2024.
The self-collection option comes at no extra charge and aims to address the declining screening rates, with 4.4 million fewer American women receiving screenings in 2021 compared to 2019. The service is not FDA approved for at-home collection and is not intended to replace regular pelvic examinations.
Quest Diagnostics (NYSE: DGX) has scheduled the release of its first quarter 2025 financial results for Tuesday, April 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Participants can join the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) using passcode '7895081'. The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until May 6, 2025, via the website or by phone at 866-361-4757 (domestic) or 203-369-0183 (international).
Quest Diagnostics (NYSE: DGX) outlined its strategic vision at its 2025 Investor Day, projecting 4-5% compound annual revenue growth and 7-9% adjusted EPS growth beyond 2025. The company's growth strategy focuses on expanding market access in physician and hospital channels, achieving double-digit growth in advanced diagnostics across five key clinical areas, and leveraging strategic partnerships.
Key initiatives include driving growth through diagnostic innovation, expanding hospital collaborative lab solutions, growing consumer-initiated testing via questhealth.com, and focusing on advanced diagnostics in oncology, cardiometabolic health, women's health, brain health, and autoimmune disorders. The company aims to achieve 3% annual productivity savings through its Invigorate initiative and modernize IT systems through Project Nova.
For Q1 2025, Quest expects weather-related impacts to create a $25 million revenue headwind and approximately $0.10 EPS impact.
Quest Diagnostics (NYSE: DGX) has announced a strategic collaboration with Google Cloud to enhance its data management and customer experience using generative AI technology. The partnership, announced on March 18, 2025, will utilize Google's Agentspace platform to connect employees and customers with enterprise-wide knowledge and automate complex tasks.
Quest will implement Google Cloud's data analytics and AI capabilities across various operations, including R&D, customer experience, and operations, with robust data privacy safeguards. The collaboration aims to help patients better understand their laboratory data and assist physicians in providing more personalized care.
With Quest processing over 200 million test requisitions and managing more than 80 billion datapoints in 2024, the partnership will leverage Google Cloud's HIPAA-compliant infrastructure and secure data storage. This initiative builds upon Quest's existing AI and automation implementations in areas such as microbiology, cytology testing, specimen processing, and customer service.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.
This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.
Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.
Quest Diagnostics (NYSE: DGX) has announced plans to host an Investor Day event on March 19, 2025 at the New York Stock Exchange. The event will feature presentations from key executives including Chairman, CEO and President Jim Davis, and Executive Vice President and CFO Sam Samad.
The leadership team will provide institutional investors and financial analysts with insights into several key areas including:
- Updated perspectives on the U.S. laboratory market
- Company's business strategy
- Capital deployment priorities
- Long-term outlook
The event requires advance registration and will be accessible via live webcast on Quest Diagnostics' Investor Relations website. An archived version of the webcast will be made available following the event's conclusion.
GRAIL (NASDAQ: GRAL) and Quest Diagnostics (NYSE: DGX) announced the integration of GRAIL's Galleri® multi-cancer early detection (MCED) test into Quest's test ordering system. This collaboration enables providers to order the Galleri test directly through Quest's Quanum laboratory portal and over 900 electronic health record systems.
The integration makes the test accessible at Quest's 7,400 patient access points nationwide, streamlining the ordering process for over 500,000 healthcare providers. The Galleri test, which detects cancer DNA fragments in blood before symptoms appear, is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older.
This development builds upon their existing collaboration since 2021, aiming to improve cancer screening accessibility. The test can detect multiple deadly cancers, including those without current recommended screening tests, which account for nearly 70% of cancer deaths.
Quest Diagnostics (NYSE: DGX) has been named to Fortune magazine's 2025 World's Most Admired Companies™ list for the 11th consecutive year. The company ranked third in the 'Health Care: Pharmacy and Other Services' category, achieving top positions in seven of nine evaluation criteria.
The selection process, conducted in collaboration with Korn Ferry, involved surveying thousands of executives, directors, and analysts who rated companies based on nine key attributes including quality of products and services, innovation, and social responsibility. Quest secured top 1 or 2 positions in areas such as quality of management, long-term investment, product and service quality, social responsibility, and people management.
With over 55,000 employees, Quest Diagnostics continues its mission of creating a healthier world under the leadership of Chairman, CEO and President Jim Davis. Companies must rank in the top half of their industry survey to be included in this prestigious list, which analyzed 650 companies in total.
